AstraZeneca's MedImmune Gets Creative In Diabetes With PCSK9/GLP-1 Fusion Product
Executive Summary
AstraZeneca PLC's MedImmune LLC will be the first drug developer to present data for a "fusion molecule" therapy combining a PCSK9 antibody with a GLP-1 peptide when a Phase I trial of its pioneering product MEDI-4166 in type 2 diabetics completes later this year. The company's head of diabetes innovative medicines, Cristina Rondinone, explains to Scrip the thought process behind the unique combination and what to expect for further development of the novel drug in 2017.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.